Dose-Dependent Valproic Acid Thrombocytopenia in Bipolar Disorder

Wyllie E, Wyllie R: Routine laboratory monitoring for serious adverse effects of antiepileptic medications: The controversy. Epilepsia 1991; 32(Suppl 5):S74-S79 Delgado MR, Riela AR, Mills J, Browne R, Roach ES: Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994; 9(3):311–314 Smith FR, Boots M: Sodium valproate and bone marrow suppression. Ann of Neurol 1980; 8(2):197–199 Tohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC: Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiat 1995; 152(3):413–418 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994 Frances A, Doherty JP, Kuhn DA: The expert consensus guideline series—Treatment of bipolar disorder. J Clin Psychiatry 1996; 57(12A):1–88 Sander JW, Trevisol-Bittencourt PC, Hart YM, Patsalos PN, Shorvon SD: The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990; 7(3):226–229 Sterker M, Berrouschot J, Schneider D: Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharm Ther 1995; 33(11):595–597 Wadelius M, Karlsson T, Wadelius C, Rane, A: Lamotrigine and toxic epidermal necrolysis. Lancet 1996; 348:1041 Loiseau P: Alterations plaquettaires au cours du traitement des epilepsies par le valproate sodium. Nouvelle Presse Med 1981; 10(46):3789–3790 May RB, Sunder TR: Hematologic manifestations of long-term valproate therapy. Epilepsia 1993; 34(6):1098–1101 Barr RD, Copeland SA, Stockwell ML, Morris N, Kelton JC: Valproic acid and immune thrombocytopenia. Arch Dis Child 1982; 57(9):681–684 Sandler RM, Emberson C, Roberts GE, Voak D, Darnborough J, Heeley AF: IgM platelet autoantibody due to sodium valproate. BMJ 1978; 2(6153):1683–1684